Jason D. Katz

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

Véronique Plantevin Krenitsky, Lisa Nadolny, Mercedes Delgado et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 112 citations · Full text

Medicinal Chemistry, Fibrosis, Medicine +4

Diastereoselective Alkylations of Oxazolidinone Glycolates:  A Useful Extension of the Evans Asymmetric Alkylation

Michael T. Crimmins, Kyle A. Emmitte, Jason D. Katz · Organic Letters · 2000 · 103 citations

Asymmetric Total Synthesis of Spongistatins 1 and 2

Michael T. Crimmins, Jason D. Katz, David G. Washburn et al. · Journal of the American Chemical Society · 2002 · 94 citations

Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models

Zhimin Li, Yushi Qiu, David Personett et al. · PLoS ONE · 2013 · 94 citations · Full text

Cns Lymphoma, Lymphoid Neoplasia, Cancer Immunosurveillance +15

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

Bo‐Sheng Pan, Grace K.Y. Chan, Mélissa Chénard et al. · Cancer Research · 2010 · 82 citations

Activated C-met Receptor, Cell Culture, Cancer Biology +19